Farnesoid X Receptor Agonist for the Treatment of Liver and Metabolic Disorders: Focus on 6-ethyl-CDCA

E-ISSN： 1875-5607|11|9|753-762

ISSN： 1389-5575

Source： Mini Reviews in Medicinal Chemistry, Vol.11, Iss.9, 2011-08, pp. : 753-762

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lepidozenolide from the liverwort Lepidozia fauriana acts as a farnesoid X receptor agonist

By Lin Hsiang-Ru

Journal of Asian Natural Products Research, Vol. 17, Iss. 2, 2015-02 ,pp. : 149-158

Taylor & Francis Ltd

Access to resources Recommend Favorite

Farnesoid X receptor agonism – a new approach to the treatment of cholesterol gallstone disease

By Doggrell Sheila A

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 4, 2005-04 ,pp. : 535-538

Informa Healthcare

Access to resources Recommend Favorite

Targeting Farnesoid-X-Receptor: From Medicinal Chemistry to Disease Treatment

Current Medicinal Chemistry, Vol. 17, Iss. 2, 2010-01 ,pp. : 139-159

Bentham Science Publishers

Access to resources Recommend Favorite

Paeoniflorin acts as a liver X receptor agonist

By Lin Hsiang-Ru

Journal of Asian Natural Products Research, Vol. 15, Iss. 1, 2013-01 ,pp. : 35-45

Taylor & Francis Ltd

Access to resources Recommend Favorite

Hologram QSAR Studies on Farnesoid X Receptor Activators

Letters in Drug Design & Discovery, Vol. 3, Iss. 4, 2006-05 ,pp. : 261-267

Bentham Science Publishers

Access to resources Recommend Favorite